new patient start impact
durabl clear guidanc impact
start align expect
modestli adjust revenu margin see
expect larg unchang pt
durabl quarter expect deliv sale vs
mse beat driven us omnipod sale mse ex-
us omnipod sale mse drug deliveri revenu
lighter vs mse due shift time product
benefit driven stock quarter
adjust stock result reflect point us omnipod momentum
deceler ex-u stabil manag comment histor
cycl eas quarter given pharmaci dash traction type
payg-model metric continu advanc rapidli make
new patient start vs last quarter total
instal base roughli total us volum go
pharmaci dash drive new patient start manag
maintain low end origin guidanc total cc
growth origin guidanc cc growth guidanc includ
expect total omnipod deliv cc growth omnipod
growth ex-u omnipod cc growth three metric
previous exhibit result vs mse
impact larg in-lin model estim
impact new patient start although assum slightli higher
percentag contribut new patient start vs underli busi
recoveri manag confirm new patient start gener
drive revenu given quarter expect new start
impact respect
impli impact vs pre-covid number
like track ahead estim impact given april
new start given impact sale funnel lag effect
discuss diabet math note may like
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
continu assum ex-u market see harder hit vs us
given site servic larg hospit base europ
impact greater
overal model us omnipod ex-
us omnipod corpor revenu model
us omnipod ex-u omnipod corpor revenu
reflect organ growth vs previou model
predic slightli wors better
continu see one durabl perform
coverag on-going shift telemedicin
payg model key differenti vs tradit tube-pump devic
telemedicin like provid underappreci advantag versu peer
world under-perform phase peer evid
durabl may drive catch-up
margin move lower given manufactur dynam due impact
volum near-term manufactur ramp next year
manag expect gross margin rang
sens improv cours
slightli signific impact model gross
margin margin confid pathway
could still possibl headwind less fear
adjust model lower
horizon commentari encourag earli march manag announc
month horizon trial paus due softwar updat see thought
announc complet softwar updat
sent fda review trial yet resum given newli requir
logist trial site overal horizon remain track launch
reflect delay vs prior estim pivot trial see
clinicaltri gov fulli enrol patient age intend
launch pediatr indic expect driven
telemedicin virtual train process pave way potenti easier
patient onboard time launch
lrp continu look achiev bia remain posit
discuss past sever quarter see path
revenu clear remain true even context covid-
headwind moreov pathway greater profit beyond
becom increasingli appar remain confid manag abil
meet lrp revenu target manag reiter today
especi given market expans natur share captur opportun
embed payg shift pharmaci increas success
model sale although impact volum
manufactur progress may lead pt origin
target see still potenti achiev nearli certain
time rais price reflect base case
sale premium high growth devic peer
million except ep
sale
sale
sale
sale
sale
sale
sale
sale
longer term omnipod growth sustain
price target reect ev sale multipl base case premium
high growth smid cap peer
remain comfort
revenu growth omnipod continu
penetr insulin-intens diabet
popul given eas use form factor
access us pharmaci
path revenu clear
driven channel shift pharmaci
payg model ex us growth
expect horizon launch
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
may gure approxim risk-neutr probabl stock reach beyond scenario
price either three-month one-year time view explan option probabl methodolog
ex us reacceler
underli growth payg model
shift pharmaci acceler us growth ap
competitor prove market expans
immateri omnipod growth greater
scale oper efcienc
pharmaci channel drive om
next year
us growth remain driven shift
pharmaci payg model ex-u
grow high-teen mdi
pediatr posit insul omnipod
ap competitor risk remain path
sale clear like
oor horizon ap launch
fail off-set competit headwind dash
 horizon adopt modest ap
timelin slip path greater protabl
becom less clear greater invest
requir support growth
shift pharmaci pay-as-you-go
distribut sustain ex us growth
path protabl improv us
horizon launch
china india
view explan region hierarchi
research highest favor quintil
ex-u growth re-acceler
greater abil drive manufactur
disclosur addit drug deliveri deal
